NCT06922344 Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor
| NCT ID | NCT06922344 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Khyber Teaching Hospital |
| Condition | Pityriasis Versicolor |
| Study Type | INTERVENTIONAL |
| Enrollment | 106 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 106 participants in total. It began in 2025-03-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study compares the efficacy of two drugs, namely flucanazole and itraconazole for the treatment of a common fungal infection of skin.
Eligibility Criteria
Inclusion Criteria: * All cases of Pityriasis versicolor Exclusion Criteria: * Patients with history of chronic renal or liver disease, malignancy , or undergoing any kind of chemotherapy or radiotherapy or having cardiac conduction abnormalities. * Patients who received any anti-fungal therapy in the last one month. * Pregnant or lactating women.
Frequently Asked Questions
Who can join the NCT06922344 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Pityriasis Versicolor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06922344 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06922344 currently recruiting?
Yes, NCT06922344 is actively recruiting participants. Visit ClinicalTrials.gov or contact Khyber Teaching Hospital to inquire about joining.
Where is the NCT06922344 trial being conducted?
This trial is being conducted at Peshawar, Pakistan.
Who is sponsoring the NCT06922344 clinical trial?
NCT06922344 is sponsored by Khyber Teaching Hospital. The trial plans to enroll 106 participants.